GSK Bio
NEWS
The discovery that immune T cells have a spectrum of responsiveness could shed light on how our immune system responds to infections and cancer, and what goes wrong in immune diseases.
Pharma and life sciences companies boost their executive ranks and boards with this week’s Movers & Shakers.
The two companies will evaluate a smartphone-based self-testing solution for COVID-19, using Luminostics’ innovative technology and Sanofi’s clinical research abilities.
Sir Andrew Witty, the former head of GlaxoSmithKline, current president of UnitedHealth Group and chief executive officer of Optum, is temporarily stepping away from his duties to co-lead a World Health Organization effort to combat COVID-19.
It’s likely that more companies and universities will add additional assets as time goes on.
The two companies are eying the second half of this year to begin clinical trials on their combined project and, if the vaccine meets expectations, the companies said it could be available for use in the second half of 2021.
Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
Companies strengthen their leadership teams and executive boards with this week’s Movers & Shakers.
JOBS
IN THE PRESS